1Guerci A, Merlin J L, Missoum N, et al. Predictive value for treatment outcome in acute myeloid leukemia of cellur daunorubicin accumulation and P-gp expression simultaneously determined by flow cytometry [J]. Blood, 1995,85: 2147-2153.
3Pavelic Z P, Reising J, Pavelic L, et al. Detection of P-glycoprotein with four monoclonal antibodies in normal and tumor tissues [J]. Arch Otolaryngol Neck Surg, 1993,119:753-757.
4Schinkel A H, Arceci R J, SmitJJM, et al. Binding properties of monoclonal antibodies recognizing external epitopes of the human MDR1 P-glycoprotein[J]. Int J Cancer,1993,55:478-484.
5Scheper R J, Bulte J W M, Breakkee J P G, et al. Monoclonal antibody JSB-1 detects a highly conserved epitope on the glycoprotein associated with multidrug-resistance [J]. Int Cancer, 1988,42: 389-394.
5Schafer D F, Son'ell M F. Hepatocellular carcinoma[J]. Lancet, 1999,353(9160):1253-1257.
6Humphries J D, Byron A, Humphries M J. Integrin ligands at a glance[J]. J Cell Sci, 2006,119(19):3901-3903.
7Kumar C C. Intergrin alpha v beta 3 as a therapeutic target for blocking tumor-induced angiogenesis[J]. Curr Drug Targets, 2003, 4(2):123-131.
8Li J, Tan H, Tong X, et al. Antisense integrin alpha V and beta 3 gene therapy suppresses subcutaneously implanted hepatocellular carcinomas[J]. Dig Liver Dis, 2007,39(6):557-565.
9Ahrens I G, Moran N, Aylward K, et al. Evidence for a differential functional regulation of the two 133-integrins αVβ3 and αIIbβ3[J]. Exp Cell Res, 2006,312(6):925-937.
10Heng B C, Cowan C M, Shubhayu B. Comparison of enzymatic and non-enzymatic means of dissociating adherent monolayers of mesenchymal stem cells[J]. Biol Procedures Online, 2009,11 (1):161-169.
